Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L17 pseudogene 52 (RPL17P52) is a processed pseudogene found in the human genome, related by sequence homology to the functional RPL17 gene, which encodes ribosomal protein L17[1][3][4]. Processed pseudogenes are genomic DNA segments derived from mRNA retrotransposition events and do not typically encode functional proteins due to disablements such as stop codons and frameshifts[3]. RPL17P52, like other ribosomal protein pseudogenes, is located throughout the genome without known regulatory or protein-coding function. Unlike its parent RPL17 gene, which participates in ribosomal structure and function, the pseudogene variant is not involved in normal protein synthesis, cellular signaling, disease, or therapeutic pathways[1][3]. It has no recognized biological activity, does not interact with drugs, nor serve as a biomarker, and is not considered a therapeutic target. If you require information about the parent, protein-coding RPL17 gene (Ribosomal protein L17), or its biological/pathological significance, that would be a distinct query since RPL17P52 itself is non-functional[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L17 pseudogene 52 (RPL17P52).